JG
Idorsia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| QUVIVIQ (daridorexant) | Insomnia Disorder | Marketed |
| TRYVIO/JERAYGO (aprocitentan) | Resistant Hypertension | Marketed |
| Cenerimod | Systemic Lupus Erythematosus (SLE) | Phase 3 |
| Selatogrel | Acute Myocardial Infarction | Phase 3 |
| Lucerastat | Fabry Disease | Phase 3 |
| ACT-539313 | Binge Eating Disorder | Phase 2b |
| ACT-1019-0460 | Undisclosed Immunology | Phase 1 |
| Vaccine Programs | Bacterial Infections (Prevention) | Preclinical/Discovery |